Core Insights - SunRock Biopharma and Chime Biologics have announced a strategic collaboration to develop SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD) [1] - The collaboration may expand into other immune-mediated inflammatory indications, indicating a broader potential market for SRB5 [1] Company Overview - SunRock Biopharma is focused on developing next-generation therapeutic antibodies [1] - Chime Biologics is recognized as a global leading contract development and manufacturing organization (CDMO) [1] Product Development - SRB5 is specifically designed to target inflammatory bowel disease (IBD) [1] - The strategic collaboration aims to leverage the strengths of both companies in the development of SRB5 [1]